The Early Detection Research Network (EDRN) is an initiative of the National Cancer Institute (NCI). EDRN was developed to help accelerate the translation of biomarker information into clinical approaches and to evaluate new and novel ways in which to test cancer in its earliest stages and access risk of cancer. As a Biomarker Reference Lab, in association with collaborators around the country, we aim to develop multiplex enzyme-linked immunosorbent assays (ELISAs) to detect targeted biomarker concentrations in human sera samples.
The goal of the Programs of Excellence in Glycosciences (PEG) is to build investigative capacity in glycosciences, and translate emerging discoveries into potential new diagnostics and clinical applications relevant to heart, lung, and blood research.
An initiative for the development and commercialization of high-value, multi-marker, diagnostic tests which will address unmet needs in gynecologic oncology and women's health. More info
As an initiative of the National Cancer Institute, the Clinical Proteomic Tumor Analysis Consortium (CPTAC) is a coordinated effort aimed at accelerating the understanding of the molecular basis of cancer by implementing applications of robust, quantitative, proteomic technologies and work flows. The goal of the Johns Hopkins University Proteome Characterization Center (PCC) is to develop a cancer proteomic biomarker pipeline. Our main focus is the characterization of TCGA ovarian tumors using mass spectrometry-based and protein microarray-based proteomic technologies for global proteomics and protein post-translational modifications. Our primary objective is to determine the effects of genomic alterations on protein levels and post-translational modifications. The Johns Hopkins PCC is comprised of researchers from Johns Hopkins, Stanford University, Virginia Tech University, Memorial Sloan Kettering Cancer Center, and the University of Chicago. More info
amfAR's mission is to end the global AIDS epidemic through innovative research. With the freedom and flexibility to respond quickly to emerging areas of scientific promise, amfAR plays a catalytic role in accelerating the pace of HIV/AIDS research and achieving real breakthroughs. Since 1985, amfAR has invested more than $517 million in its programs and has awarded more than 3,300 grants to research teams worldwide. Through its $100 million Countdown to a Cure for AIDS initiative, amfAR aims to develop the scientific basis for a cure by 2020.